CONFIDENCE (2025) — Trial Summary
CONFIDENCE (2025): The CONFIDENCE phase 2 trial evaluated simultaneous initiation of finerenone (nonsteroidal MRA) plus empagliflozin (SGLT2 inhibitor) versus either agent alone in patients with CKD and type 2 diabetes, testing the combination approach to kidney protection.
References
- Agarwal R, Green JB, Heerspink HJL, et al. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025;393:533-543.